Early versus delayed enalapril in patients with left ventricular systolic dysfunction: Impact on morbidity and mortality 15 years after the SOLVD trial

To the Editor: The Studies Of Left Ventricular Dysfunction (SOLVD) trial showed that enalapril, an angiotensin-converting enzyme (ACE) inhibitor, reduced morbidity and mortality in patients with ejection fractions ≤35% ([1,2][1]), including the risks of myocardial infarction and unstable angina ([